Xarelto 15mg Tablet contains rivaroxaban, a direct oral anticoagulant that selectively inhibits Factor Xa, an essential component in the coagulation cascade responsible for thrombin generation and clot formation. This medication is indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), and for stroke prevention in patients with non-valvular atrial fibrillation. By inhibiting Factor Xa, Xarelto effectively reduces the risk of clot formation without the need for routine coagulation monitoring, offering a convenient alternative to traditional anticoagulants such as warfarin. The 15mg dosage is typically prescribed for the treatment phase of DVT and PE or for extended prophylaxis following initial treatment. Xarelto demonstrates predictable pharmacokinetics and pharmacodynamics, with rapid onset of action and a half-life conducive to once or twice daily dosing. Caution is advised in patients with renal impairment, hepatic dysfunction, or increased bleeding risk. Contraindications include active pathological bleeding and hypersensitivity to rivaroxaban. Patients should be monitored for signs of bleeding and counseled on adherence and potential drug interactions. Xarelto 15mg Tablet is a critical agent in the management of thromboembolic diseases, offering efficacy and safety when used as directed.